Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06906341 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 16, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 1 of 49 sitesv10
  2. Study sites: 45 to 49 Secondary endpoints: 6 to 9v9 Show 1 more changeShow less
    • Secondary endpoints: 6 to 9

    See this version in full on ClinicalTrials.gov ↗

  3. Enrollment target: 90 to 270 Study sites: 39 to 45 · Eligibility criteria shortened, about 56 words · Secondary endpoints: 5 to 6 · 3 morev8 Show 6 more changesShow less
    • Study sites: 39 to 45
    • Eligibility criteria shortened, about 56 words
    • Secondary endpoints: 5 to 6
    • Study description expanded, about 54 words
    • Study arms: 1 to 3
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 23 to 39v7
  5. Study sites: 4 to 23v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 3 to 4v5
  2. Study sites: 1 to 3 Eligibility criteria expanded, about 5 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2025 to Apr 11, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Apr 2025 to Apr 11, 2025
    • Site details revised
  4. Study sites: 0 to 1v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Trial Details
NCT Number NCT06906341
Lead Sponsor Corcept Therapeutics
Conditions Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov